The incidence, treatment strategies and outcomes of acute coronary syndromes in the "reperfusion network" of different hospital types in the Czech Republic: results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
17442424
DOI
10.1016/j.ijcard.2007.02.036
PII: S0167-5273(07)00527-X
Knihovny.cz E-zdroje
- MeSH
- beta blokátory terapeutické užití MeSH
- dospělí MeSH
- incidence MeSH
- infarkt myokardu diagnóza epidemiologie terapie MeSH
- inhibitory ACE terapeutické užití MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- koronární angiografie MeSH
- koronární bypass MeSH
- lidé středního věku MeSH
- lidé MeSH
- mortalita v nemocnicích MeSH
- nestabilní angina pectoris diagnóza epidemiologie terapie MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- statiny terapeutické užití MeSH
- trombolytická terapie metody MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- beta blokátory MeSH
- inhibitory ACE MeSH
- inhibitory agregace trombocytů MeSH
- statiny MeSH
AIMS: To analyze the incidence, treatment strategies and outcomes of acute coronary syndromes (ACS) in Czech population. METHODS AND RESULTS: ACS diagnosis was confirmed in 1345 of 1921 (70%) consecutively admitted patients with suspected ACS. ACS incidence was 3248 cases/million/year and the annual incidence of confirmed myocardial infarction was 1960 per million. In-hospital mortality was 5.1% (10.0% with Q-MI, 4.4% with non-Q-MI, and 0.9% with UAP). Coronary angiography was performed in 92% of STEMI (followed by primary PCI in 83%, by CABG in 3%, by conservative therapy in 6%). Thrombolysis was used in only 1% of patients. Reperfusion therapy was thus used in 87% of all STEMI patients. Discharge medication included aspirin in 95%, a statin in 76%, a beta-blocker in 78%, an ACE inhibitor in 50%, clopidogrel in 60%, and ticlopidine in 4% of patients. CONCLUSIONS: In-hospital mortality of ACS in the Czech network of PCI and non-PCI hospitals is low. Nationwide application of primary PCI strategy for STEMI is feasible and increases the overall use of reperfusion therapy.
Citace poskytuje Crossref.org
Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic
ECG in patients with acute heart failure can predict in-hospital and long-term mortality